FUTURE OF SYSTEMIC THERAPY IN ONCOUROLOGY: TARGETED AND IMMUNOTHERAPY
Authors: F.V. Moiseenko
Targeted therapy and immune checkpoint inhibition drastically changed the perspectives of patients with urological cancers. Monotherapy with checkpoint inhibitors is on different stages of clinical investigation, determined by particular tumor prevalence. In this article authors describe current situation in the field of new therapies and express an opinion on their development.